EMPEROR_HFpEF
A phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with preserved Ejection Fraction (HFpEF).
- Stage
- klaar
- Medicine
- empagliflozin
- Population
- Hartfalen
- Phase
- III
- First Patient In
- 25 August 2017
- Last Patient In
- 10 January 2020
- Last Patient Last Visit
- 18 April 2021
Study Director
